Scimar is raising funds on Texture Capital through Reg A+ crowdfunding. The company discovered the hepatalin hormone and is revolutionizing the prevention, diagnosis, and treatment of type 2 diabetes. Scimar is developing medical interventions based on the science of hepatalin to handle excess glucose in the body and bring an end to type 2 diabetes. The company has currently conceived four products, including SciMar NuPa Test, SciMar NuPa Daily, SciMar NuPa Renew, and Hepatalin-S, and plans to grow more. Dr. W. Wayne Lautt and Mick Lautt founded Scimar in 2009. The current crowdfunding campaign has a maximum target of $55 million. The campaign proceeds will be used for research and development, expanded infrastructure, cost of capital, facilities, operations, brand building, and accounting expenses.